ReviewDrug design, development and therapy2026
Targeting Cancer-Associated Fibroblasts with Small-Molecule Inhibitors: Molecular Mechanisms and Therapeutic Potential.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The multifaceted role of cancer-associated fibroblasts (CAFs) in orchestrating extracellular matrix remodeling, immune evasion, and therapeutic resistance positions these stromal cells as critical yet underexploited nodes in the tumor microenvironment (TME). While small-molecule agents offer practical advantages over biologics for stromal modulation, a systematic understanding of their mechanistic diversity and translational barriers remains incomplete. To address this gap, this review consolidates current knowledge on the principal signaling axes-TGF-β/STAT3, NF-κB, Notch, Hedgehog, PI3K/AKT, and CXCL12/CXCR4-that sustain CAF activation and pathogenic functions. Distinct from prior CAF reviews, particular emphasis is placed on the structure-activity refinement (SAR) of fibroblast activation protein (FAP)-targeted small-molecule ligands and on pharmacokinetic optimization via fatty acid conjugation and porphyrin integration that substantially improve tumor retention. Representative pharmacological inhibitors-including nicotinamide N-methyltransferase (NNMT), phosphodiesterase 5A (PDE5A), and NADPH oxidase 4 (NOX4) inhibitors-are evaluated for their capacities to remodel immunosuppressive networks, with attention to their synergism when combined with chemotherapeutic agents, immune checkpoint blockers, or antibody-drug conjugates. Emerging evidence indicates that CAF heterogeneity and plasticity pose fundamental obstacles to monotherapy efficacy, whereas rationally designed combination regimens produce superior antitumor outcomes in preclinical models. We further identify key knowledge gaps-including the lack of CAF-subset-selective drugs, unresolved pharmacotoxicology of pan-FAP inhibition, and limited biomarker-guided patient stratification-and discuss translational and regulatory barriers that must be overcome before widespread clinical adoption. Collectively, this review argues that the future of CAF-directed pharmacotherapy lies not in indiscriminate depletion but in subset-selective reprogramming, and that clinical success will increasingly depend on biomarker-guided patient stratification and mechanistically anchored multidrug scheduling rather than on isolated target inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.